药捷安康-B(02617)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02617 药捷安康-B

休市中 10-30 16:08:08

8.400

-0.255

-2.95%

最高9.395	最低8.400	成交量1,336万
今开8.870	昨收8.655	日振幅11.50%
总市值34.27亿	流通市值26.29亿	总股本4.08亿
成交额1.20亿	换手率4.27%	流通股本3.13亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02617","market":"HK","secType":"STK","nameCN":"药捷安康-B","latestPrice":8.4,"timestamp":1793347688008,"preClose":8.655,"halted":0,"volume":13363000,"delay":0,"changeRate":-0.02946273830155968,"floatShares":313000000,"shares":408000000,"eps":-0.76,"marketStatus":"休市中","change":-0.255,"latestTime":"10-30 16:08:08","open":8.87,"high":9.395,"low":8.4,"amount":119823542,"amplitude":0.114962,"askPrice":8.4,"askSize":2500,"bidPrice":8.39,"bidSize":7500,"shortable":3,"etf":0,"ttmEps":-0.776468,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1793583000000},"marketStatusCode":7,"adr":0,"listingDate":1750608000000,"exchange":"SEHK","adjPreClose":8.655,"openAndCloseTimeList":[[1793323800000,1793332800000],[1793336400000,1793347200000]],"volumeRatio":4.696021928608013,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02617","defaultTab":"news","newsList":[{"id":"2680720168","title":"药捷安康－Ｂ(02617.HK)：联交所授出实行H股全流通的上市批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2680720168","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680720168?lang=zh_cn&edition=full","pubTime":"2026-11-01 19:58","pubTimestamp":1793534283,"startTime":"0","endTime":"0","summary":"格隆汇11月1日丨药捷安康－Ｂ(02617.HK)公告，董事会欣然宣布，联交所已授出由公司10名股东(\"参与股东\")所持有的44,971,128股非上市股份转换而成的44,971,128股H股上市及买卖批准。联交所于2026年10月30日授出上市批准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20261101/32412899.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["02617","BK1161","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680209677","title":"药捷安康-B(02617.HK)：联交所授出实行H股全流通的上市批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2680209677","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680209677?lang=zh_cn&edition=full","pubTime":"2026-11-01 18:40","pubTimestamp":1793529641,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680209716","title":"药捷安康：4497万股非上市股份转H股获批 H股占比将升至87.70%","url":"https://stock-news.laohu8.com/highlight/detail?id=2680209716","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680209716?lang=zh_cn&edition=full","pubTime":"2026-11-01 18:35","pubTimestamp":1793529300,"startTime":"0","endTime":"0","summary":"11月1日，药捷安康-B（02617）发布公告，联交所已授出本公司10名股东所持有的4497万股非上市股份转为H股的上市批准，上述股份占本公司已发行股本总额约11.01%。转换后本公司H股的股份数目将由3.13亿股增至3.58亿股，占比将由76.69%上升至87.70%。非上市股份将减少至5026万股，占比下降至12.30%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202611013917734910.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202611013917734910.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113668038","title":"药捷安康-B回购3.25万股股份，总额约28.03万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1113668038","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1113668038?lang=zh_cn&edition=full","pubTime":"2026-10-27 19:01","pubTimestamp":1793098896,"startTime":"0","endTime":"0","summary":"药捷安康-B于2026年10月27日发布公告，披露公司当日通过香港联交所场内回购3.25万股H股，约占回购前已发行股本的0.01%。每股回购价区间为8.53港元至8.72港元，本次回购合计支付280,290.01港元，折合约28.03万港元。药捷安康-B于2026年6月18日获股东大会授权可回购31,268,767股，当前已回购的股份数累计达861,000股，占授权规模的0.28%。公司确认已严格遵守香港联交所证券上市规则及相关法律法规，相关回购事宜均经公司董事会批准。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"药捷安康-B回购3.25万股股份，总额约28.03万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678194239","title":"药捷安康-B：收到中国证监会H股全流通备案通知书 涉及4497.11万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2678194239","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678194239?lang=zh_cn&edition=full","pubTime":"2026-10-26 22:51","pubTimestamp":1793026260,"startTime":"0","endTime":"0","summary":"南财智讯10月26日电，药捷安康-B（02617.HK）发布内幕消息公告，公司建议将10名股东持有的4497.11万股内资股（占公司已发行股本总额约11.01%）实施H股全流通。公司于2026年10月26日收到中国证监会就实施H股全流通发出的备案通知书，已完成上述4497.11万股内资股转换为H股的实施备案。备案通知书有效期为自发出日期起计12个月。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610263908633664.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610263908633664.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678194155","title":"药捷安康-B(02617.HK)收到中国证监会就实施本公司H股全流通发出的备案通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2678194155","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678194155?lang=zh_cn&edition=full","pubTime":"2026-10-26 22:50","pubTimestamp":1793026200,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147010453","title":"药捷安康-B回购52,500股股份，涉资约46.69万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1147010453","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1147010453?lang=zh_cn&edition=full","pubTime":"2026-10-26 20:12","pubTimestamp":1793016724,"startTime":"0","endTime":"0","summary":"药捷安康(南京)科技股份有限公司于2026年10月26日向香港联合交易所提交翌日报表，披露当日于场内执行股份回购，导致已发行股本出现变动。公司于2026年10月26日回购H股普通股52,500股，约占回购前公司已发行股份总数的0.02%。每股价格在8.77港元至8.965港元之间，总耗资约46.69万港元。本次回购完成后，公司已发行股份总数变更为312,519,173股，库藏股数量则增至828,500股，合计股份数量为313,347,673股。回购授权于2026年6月18日获得股东大会通过，授权回购股份总数为31,268,767股。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"药捷安康-B回购52,500股股份，涉资约46.69万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678980671","title":"药捷安康-B(02617)10月26日斥资46.7万港元回购5.25万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2678980671","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678980671?lang=zh_cn&edition=full","pubTime":"2026-10-26 20:11","pubTimestamp":1793016668,"startTime":"0","endTime":"0","summary":"智通财经APP讯，药捷安康-B(02617)发布公告，于2026年10月26日斥资46.7万港元回购5.25万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1512684.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678119806","title":"药捷安康-B(02617.HK)10月26日斥资46.7万港元回购5.25万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2678119806","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678119806?lang=zh_cn&edition=full","pubTime":"2026-10-26 20:11","pubTimestamp":1793016668,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197503780","title":"药捷安康-B回购52,500股股份，涉资约45.87万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1197503780","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1197503780?lang=zh_cn&edition=full","pubTime":"2026-10-23 17:07","pubTimestamp":1792746437,"startTime":"0","endTime":"0","summary":"药捷安康(南京)科技股份有限公司于2026年10月23日公告披露，公司于当日通过香港联交所场内回购股份52,500股，约占现有已发行股份的0.02%。本次回购价格区间为每股8.55港元至8.79港元，合计耗资约45.87万港元。回购完成后，公司已发行股份总数仍为313,347,673股，其中不包括库存股份的已发行股份数为312,571,673股，库存股份数增至776,000股。公司表示，本次回购已获得董事会正式授权，并遵守了香港联交所相关上市规则及适用的法律法规。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"药捷安康-B回购52,500股股份，涉资约45.87万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677494364","title":"港股异动 | 药捷安康-B(02617.HK)涨超4% 捷恩泰®已于多个省份开出首批临床处方","url":"https://stock-news.laohu8.com/highlight/detail?id=2677494364","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677494364?lang=zh_cn&edition=full","pubTime":"2026-10-23 14:26","pubTimestamp":1792736810,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197898257","title":"药捷安康-B回购5,500股并发行660,000股H股，已发行股本变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1197898257","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1197898257?lang=zh_cn&edition=full","pubTime":"2026-10-22 20:25","pubTimestamp":1792671947,"startTime":"0","endTime":"0","summary":"2026年10月22日，药捷安康(南京)科技股份有限公司公告显示，公司近期进行了H股回购及新股增发操作，已发行股本与库藏股数相应变动。根据公告，2026年10月15日，公司依据2026年6月18日采纳的H股股份奖励计划，向相关参与人发行660,000股新H股，约占该次发行前公司已发行股份总数的0.21%。上述回购股份将以库藏股份形式持有。回购完成后，公司将于2026年11月21日之前暂缓开展新股发行或进一步出售、转让库藏股的相关事宜。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"药捷安康-B回购5,500股并发行660,000股H股，已发行股本变动","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677680969","title":"药捷安康-B(02617)10月22日耗资约4.72万港元回购5500股","url":"https://stock-news.laohu8.com/highlight/detail?id=2677680969","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677680969?lang=zh_cn&edition=full","pubTime":"2026-10-22 20:23","pubTimestamp":1792671806,"startTime":"0","endTime":"0","summary":"智通财经APP讯，药捷安康-B(02617)公布，2026年10月22日耗资约4.72万港元回购5500股股份。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1511074.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189695147","title":"药捷安康-B（02617）披露捷恩泰®进入全国商业化销售阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=1189695147","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1189695147?lang=zh_cn&edition=full","pubTime":"2026-10-22 12:06","pubTimestamp":1792641964,"startTime":"0","endTime":"0","summary":"2026年10月22日，药捷安康（南京）科技股份有限公司发布自愿性公告，披露核心产品捷恩泰的最新商业化进展。公司公告显示，捷恩泰首批产品已于2026年9月9日完成生产并出厂；9月17日，首批产品通过商业渠道发货至全国各地药房，并在北京大学肿瘤医院开出全国首张处方，标志着捷恩泰正式进入国内商业化销售阶段。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677980435","title":"药捷安康-B(02617)：捷恩泰®已于多个省份开出首批临床处方 全国多地DTP药房同步完成铺货","url":"https://stock-news.laohu8.com/highlight/detail?id=2677980435","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677980435?lang=zh_cn&edition=full","pubTime":"2026-10-22 12:05","pubTimestamp":1792641935,"startTime":"0","endTime":"0","summary":"2026年9月9日，捷恩泰首批产品已完成生产并顺利出厂。2026年9月17日，捷恩泰首批产品正式从商业渠道发货，发往全国各地药房，正式开启全国商业化供应;同日，捷恩泰在北京大学肿瘤医院开出全国首张处方，标志着捷恩泰在国内正式进入商业化销售阶段。近期，捷恩泰在北京、上海、广东、江苏等多个省份开出首批临床处方，全国多地DTP药房同步完成铺货。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1510598.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02617","BK1161","DTP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182209117","title":"药捷安康-B更新9月股份变动月报表，股本保持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1182209117","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1182209117?lang=zh_cn&edition=full","pubTime":"2026-10-05 17:17","pubTimestamp":1791191860,"startTime":"0","endTime":"0","summary":"药捷安康（南京）科技股份有限公司于2026年10月5日披露截至2026年9月30日的股份变动月报表，显示报告期内各类股份无新增发行或回购，整体股本保持稳定。报告期末，公司法定注册股本总额为人民币407,918,633元，其中H股法定注册股本为人民币312,687,673元，非上市普通股法定注册股本为人民币95,230,960元。H股奖励计划下已有2,442,000份股票期权结存数保持不变。另有2026年H股奖励计划股份授权，但本月内未实际导致已发行股份总数变动。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107407294","title":"药捷安康-B2026年中期营收0.35亿元，经调整净亏损0.95亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1107407294","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1107407294?lang=zh_cn&edition=full","pubTime":"2026-09-21 20:13","pubTimestamp":1789992799,"startTime":"0","endTime":"0","summary":"2026年上半年，药捷安康-B实现营收人民币3545.50万元，而上年同期尚无收入。本期经调整净亏损约人民币0.95亿元，较上年同期的经调整净亏损进一步收窄。经营活动现金流出净额约为人民币1.06亿元，较上年同期的1.09亿元小幅改善。成本结构方面，报告期内研发投入约人民币1.10亿元，同比上升11.7%，研发投入占收入比超过3100%。管理费用约人民币2306.00万元，同比下降约16.1%。主要收入来自与合作及授权协议相关的一次性预付款收入合计人民币3545.50万元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"药捷安康-B2026年中期营收0.35亿元，经调整净亏损0.95亿元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669315301","title":"港股异动 | 药捷安康-B(02617)涨超11% 替恩戈替尼mCRPC中国II期临床完成首例给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2669315301","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669315301?lang=zh_cn&edition=full","pubTime":"2026-09-21 10:37","pubTimestamp":1789958272,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，药捷安康-B(02617)涨超11%，截至发稿，涨11.37%，报11.17港元，成交额1.03亿港元。消息面上，9月18日晚，药捷安康公告，公司核心产品替恩戈替尼(捷恩泰®， Tinengotinib, TT-00420)联合新型内分泌治疗(NHT)用于经治后进展的转移性去势抵抗性前列腺癌(mCRPC)中国II期临床试验，于近日完成首例患者给药。此外，9月17日，药捷安康宣布，其核心产品捷恩泰®（替恩戈替尼片）首批产品正式从商业渠道发货，发往全国各地药房，捷恩泰®正式开启全国商业化供应，标志着这款全球首个解决FGFR抑制剂耐药的胆管癌靶向药即将陆续抵达全国各地患者手中。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1498542.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02617","VXUS","BK1161","BK4585","KCAI","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668923201","title":"药捷安康-B：捷恩泰获纳入CSCO胆道恶性肿瘤诊疗指南(2026)","url":"https://stock-news.laohu8.com/highlight/detail?id=2668923201","media":"财中社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668923201?lang=zh_cn&edition=full","pubTime":"2026-09-18 20:05","pubTimestamp":1789733100,"startTime":"0","endTime":"0","summary":"9月18日，药捷安康-B（02617）发布公告，公司自主研发的捷恩泰?（替恩戈替尼）被纳入《中国临床肿瘤学会（CSCO）胆道恶性肿瘤诊疗指南（2026）》，作为晚期胆道恶性肿瘤治疗的II级推荐2A类。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609183878777228.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609183878777228.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142095939","title":"药捷安康-B（02617）完成替恩戈替尼联合NHT治疗mCRPC中国Ⅱ期临床首例给药","url":"https://stock-news.laohu8.com/highlight/detail?id=1142095939","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1142095939?lang=zh_cn&edition=full","pubTime":"2026-09-18 18:55","pubTimestamp":1789728930,"startTime":"0","endTime":"0","summary":"2026年9月18日，药捷安康-B公告称，公司核心产品替恩戈替尼联合新型内分泌治疗用于经治后进展的转移性去势抵抗性前列腺癌中国Ⅱ期临床试验已完成首例患者给药。替恩戈替尼是全球首个同时抑制FGFR/JAK通路并已在mCRPC中显示临床疗效的多靶点小分子激酶抑制剂。替恩戈替尼单药治疗mCRPC已于2025年6月获得美国FDA快速通道资格。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.transtherabio.com","stockEarnings":[{"period":"1week","weight":-0.046},{"period":"1month","weight":-0.2322},{"period":"3month","weight":-0.1558},{"period":"6month","weight":-0.8372},{"period":"1year","weight":-0.9516},{"period":"ytd","weight":-0.9269}],"compareEarnings":[{"period":"1week","weight":0.0087},{"period":"1month","weight":-0.0536},{"period":"3month","weight":-0.1001},{"period":"6month","weight":-0.0963},{"period":"1year","weight":-0.1137},{"period":"ytd","weight":-0.0911}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"药捷安康（南京）科技股份有限公司是一家从事生物制药的中国公司，主要专注于发现及开发肿瘤、炎症及心脏代谢疾病小分子创新疗法。该公司的核心产品Tinengotinib是一种处于注册临床阶段的内部发现和开发的MTK抑制剂，适用于某些复发或难治的耐药实体瘤。该公司的肿瘤产品线包括TT-00973（针对 AXL）、TT-01488（用于血液系统恶性肿瘤）、TT-01688（用于炎症性疾病）和 TT-00920（用于慢性心力衰竭）。这些产品能够对多种癌症类型（包括前列腺癌、肝癌、乳腺癌和BTC）产生疗效。它还可用于治疗肝细胞癌、乳腺癌、胆道癌和Pan-FGFR实体瘤。","exchange":"SEHK","name":"药捷安康-B","nameEN":"TRANSTHERA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"药捷安康-B(02617)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供药捷安康-B(02617)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"药捷安康-B,02617,药捷安康-B股票,药捷安康-B股票老虎,药捷安康-B股票老虎国际,药捷安康-B行情,药捷安康-B股票行情,药捷安康-B股价,药捷安康-B股市,药捷安康-B股票价格,药捷安康-B股票交易,药捷安康-B股票购买,药捷安康-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"药捷安康-B(02617)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供药捷安康-B(02617)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}